REG - Oxford BioDynamics - Result of General Meeting/PDMR Dealings
07/11/2025 11:45
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251107:nRSG7093Ga&default-theme=true
RNS Number : 7093G Oxford BioDynamics PLC 07 November 2025
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW
ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER
JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE
MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO
SHAREHOLDERS OF THE COMPANY DATED 22 OCTOBER 2025.
Oxford BioDynamics PLC
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Result of General Meeting
Director/PDMR Dealings
7 November 2025 - Oxford BioDynamics PLC (AIM: OBD), a biotechnology company
developing precision medicine tests based on the EpiSwitch® 3D genomics
platform announces that the resolutions proposed at the General Meeting of the
Company, held earlier today, were duly passed.
Further to the passing of the resolutions at the General Meeting, applications
have been made for 2,333,333,326 new ordinary shares of £0.001 each in the
capital of the Company ("Ordinary Shares"), to be issued pursuant to the
fundraising announced on 22 October 2025 (the "Fundraising"), to be admitted
to trading on AIM, comprising: (i) 208,333,332 Placing Shares (the "VCT/EIS
Placing Shares"); and (ii) 2,093,333,329 Placing Shares (the "General Placing
Shares") and 31,666,665 Subscription Shares.
It is expected that admission of the VCT/EIS Placing Shares ("VCT/EIS
Admission") will take place, and trading in the VCT/EIS Placing Shares will
commence at 8.00 a.m. on 10 November 2025 and that admission of the General
Placing Shares and the Subscription Shares ("General Admission") will take
place, and trading in the General Placing Shares and the Subscription Shares
will commence at 8.00 a.m. on 11 November 2025.
Following VCT/EIS Admission, the Company's issued ordinary share capital and
total voting rights will consist of 2,165,910,973 Ordinary Shares. Following
General Admission, the Company's issued ordinary share capital and total
voting rights will consist of 4,290,910,967 Ordinary Shares. These figures
should be used by shareholders as the denominator for the calculation by which
they determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
The total new Ordinary Shares subscribed for pursuant to the Fundraising by
the Directors and PDMRs who are participating in the Fundraising, are set out
below:
Director/PDMR Existing beneficial shareholding Fundraising Shares Beneficial shareholding following the Fundraising Shareholding as a percentage of the Enlarged Share Capital
Alexandre Akoulitchev 7,562,296 6,666,666 14,228,962 0.33%
Stephan Diggle(1) 251,876,178 366,666,666 618,542,844 14.4%
Thomas Guiel 1,288,146 5,000,000 6,288,146 0.15%
Peter Presland 3,398,553 3,333,333 6,731,886 0.16%
Iain Ross 10,000,000 13,333,333 23,333,333 0.54%
Paul Stockdale 3,077,919 3,333,333 6,411,252 0.15%
(1) Stephen Diggle's beneficial shareholding is held through the Vulpes Life
Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
Capitalised terms used but not otherwise defined in this announcement have the
meanings set out in the circular published on 22 October 2025.
For more information:
Oxford BioDynamics PLC +44 (0)1865 518910
Iain Ross, Executive Chairman
Paul Stockdale, CFO
Oak Securities - Sole Broker to the Fundraising +44 (0)20 3973 3678
Matthew Clarke / Tim Dainton / Calvin Man
Shore Capital - Nominated Adviser +44 (0)20 7408 4090
Stephane Auton / Lucy Bowden
Camarco - Financial PR +44 (0)20 3757 1980
Marc Cohen / Tilly Butcher / Fergus Young
OBDFinancial@camarco.co.uk
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
Director/PDMR Dealings
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Alexandre Akoulitchev
2 Reason for the notification
a) Position/status Chief Scientific Officer, Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.003 6,666,666
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 November 2025
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 November 2025
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Vulpes Investment Management (a PCA of Stephen Diggle) through Vulpes Testudo
Fund
2 Reason for the notification
a) Position/status Person closely associated with Non-Executive Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.003 366,666,666
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 November 2025
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 November 2025
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Thomas Guiel
2 Reason for the notification
a) Position/status Chief Operating Officer, PDMR
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.003 5,000,000
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 November 2025
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 November 2025
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Peter Presland
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.003 3,333,333
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 November 2025
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 November 2025
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Iain Ross
2 Reason for the notification
a) Position/status Executive Chairman, Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.003 13,333,333
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 November 2025
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 November 2025
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Paul Stockdale
2 Reason for the notification
a) Position/status Chief Financial Officer, Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.003 3,333,333
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 7 November 2025
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 November 2025
f)
Place of the transaction
Off market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMZZMGMMNNGKZM
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Oxford Biodynamics
See all newsREG - Oxford BioDynamics - Preliminary Results and Notice of AGM
AnnouncementREG - Oxford BioDynamics - Notice of Results
AnnouncementREG - Oxford BioDynamics - Statement re share price, update on EpiSwitch PSE
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
Announcement